Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Chronic Rhinosinusitis with Nasal Polyps Long-term Extension
CTR20232213Phase 2Completed
- Sponsor
- Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd.. Started Jul 2023; status: completed.
02
Drugs
telikibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20232213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232213.